Rooting for a come-from-behind win, Blackstone infuses $330M into Sanofi's CD38 development plan
Sanofi is getting a little bit of help to expand its Sarclisa franchise, with Blackstone Life Sciences putting down close to $330 million (€300 million) to fund clinical trials and related costs for a subcutaneous formulation of the drug.
In exchange, Blackstone earns the right to garner royalties on future sales.
While Sanofi had placed high hopes on Sarclisa as a bellwether for its oncology pipeline, the anti-CD38 therapy had struggled on uptake, as it was first approved shortly before the WHO declared a global pandemic in 2020, limiting patient access. The French drugmaker also faces a formidable incumbent in J&J’s Darzalex, which hits the same target.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.